Skip to main content

Advertisement

SpringerLink
Log in

Rheumatic manifestations of pituitary tumors

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Pituitary tumors may cause rheumatologic problems as a result of underproduction or overproduction of one pituitary hormone. Excessive growth hormone causes destruction of cartilage by a direct action. Facial and acral changes and arthralgias may be some of the first symptoms of acromegaly. The arthritis associated with acromegaly is often devastating. Carpal tunnel syndrome is very common in patients with acromegaly. Adrenocorticotropin (ACTH) has indirect effects via the action of glucocorticoid on bones, muscles, and the immune system. Proximal muscle weakness is a characteristic feature of Cushing’s syndrome. Patients with Cushing’s syndrome commonly have osteopenia and osteoporosis that lead to an increase in bone fractures. Avascular necrosis is associated with exogenous steroid administration. The effects of too much glucocorticoid or too rapid withdrawal can be severe. Gonadotropins act via the gonadal steroids and protect bone mass from loss. Prolactin is less involved in rheumatologic disease; the data for which are limited in humans. Pituitary tumors can have manifestations similar to rheumatologic disorders and should be included in the differential diagnosis of these diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Alexander L, Appleton D, Hall R, Ross WM, Wilkinson R:Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol (Oxf) 1980, 12:71–79.

    Article  CAS  Google Scholar 

  2. Bengtsson BA, Eden S, Ernest I, Oden A, Sjogren B:Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand 1988, 223:327–335.

    Article  PubMed  CAS  Google Scholar 

  3. Podgorski M, Robinson B, Weissberger A, et al.: Articular manifestations of acromegaly. Aust N Z J Med 1988, 18:28–35.

    PubMed  CAS  Google Scholar 

  4. Colao A, Marzullo P, Vallone G, et al.: Reversibility of joint thickening in acromegalic patients: an ultrasonography study. J Clin Endocrinol Metab 1998, 83:2121–2125.

    Article  PubMed  CAS  Google Scholar 

  5. Bluestone R, Bywaters EG, Hartog M, Holt PJ, Hyde S:Acromegalic arthropathy. Ann Rheum Dis 1971, 30:243–258.

    Article  PubMed  CAS  Google Scholar 

  6. Dons RF, Rosselet P, Pastakia B, Doppman J, Gorden P:Arthropathy in acromegalic patients before and after treatment: a long-term follow-up study. Curr Opin Rheumatol 1988, 28:515–524.

    CAS  Google Scholar 

  7. Lacks S, Jacobs RP: Acromegalic arthropathy: a reversible rheumatic disease. J Rheumatol 1986, 13:634–636.

    PubMed  CAS  Google Scholar 

  8. Layton MW, Fudman EJ, Barkan A, Braunstein EM, Fox IH:Acromegalic arthropathy: characteristics and response to therapy. Arthritis Rheum 1988, 31:1022–1027.

    Article  PubMed  CAS  Google Scholar 

  9. Detenbeck LC, Tressler HA, O’Duffy JD, Randall RV: Peripheral joint manifestations of acromegaly. Clin Orthop 1973, 91:119–127.

    Article  PubMed  Google Scholar 

  10. Lesse GP, Fraser WD, Farquharson R, Hipkin L, Vora JP:Gonadal status is an important determinant of bone density in acromegaly. Curr Opin Rheumatol 1998, 48:59–65. Gonadal status is a major determinant of bone mineral density (BMD) in patients with acromegaly. Patients with eugonadal acromegaly have increased lumbar spine and femoral neck BMD compared with the general population and patients with hypogonadal acromegaly. Patients with hypogonadal acromegaly have decreased lumbar spine and femoral neck BMD compared with the general population.

    CAS  Google Scholar 

  11. Steinbach HL, Feldman R, Goldberg MB: Acromegaly. Radiology 1959, 72:535–549.

    PubMed  CAS  Google Scholar 

  12. Jones DR, Bahn RC, Randall RV, Sullivan CR: The human costochondral junction, II: Patients with acromegaly. Mayo Clin Proc 1969, 44:330–334.

    PubMed  CAS  Google Scholar 

  13. Jenkins PJ, Sohaib SA, Akker S, et al.: The pathology of median neuropathy in acromegaly. Ann Intern Med 2000, 133:197–201. Magnetic resonance imaging (MRI) shows that edema of the median nerve within the carpal tunnel rather than extrinsic compression from increased volume of the carpal tunnel contents is the predominant pathology of median neuropathy in acromegaly.

    PubMed  CAS  Google Scholar 

  14. O’Duffy JD, Randall RV, MacCarty CS: Median neuropathy (carpal-tunnel syndrome) in acromegaly. A sign of endocrine overactivity. Ann Intern Med 1973, 78:379–383.

    PubMed  Google Scholar 

  15. Baum H, Ludecke DK, Herrmann HD: Carpal tunnel syndrome and acromegaly. Acta Neurochir (Wien) 1986, 83:54–55.

    Article  CAS  Google Scholar 

  16. Kameyama S, Tanaka R, Hasegawa A, Tamura T, Kuroki M:Subclinical carpal tunnel syndrome in acromegaly. Neurol Med Chir (Tokyo) 1993, 33:547–551.

    Article  CAS  Google Scholar 

  17. Wilder RL, Sternberg EM: Neuroendocrine hormonal factors in rheumatoid arthritis and related conditions. Curr Opin Rheumatol 1990, 2:436–440.

    Article  PubMed  CAS  Google Scholar 

  18. Nagy E, Berczi I, Friesen HG: Regulation of immunity in rats by lactogenic and growth hormones. Acta Endocrinol (Copenh) 1983, 102:351–357.

    CAS  Google Scholar 

  19. Read RC, Watt I, Dieppe PA: Rheumatoid arthritis and acromegaly —effect of growth factors on RA? Br J Rheumatol 1988, 27:242–243.

    Article  PubMed  CAS  Google Scholar 

  20. Prier A, Bloch-Michel H, Salomon A, Schanen A, Merlet C:[Cauda equina syndrome and ankylosing spondylitis. Association with acromegaly. A myelographic and tomodensitometric study of the lumbar canal]. J Sem Hop 1983, 59:1243–1247.

    CAS  Google Scholar 

  21. Ionescu N: [Acromegaly associated with ankylopoeitic spondylitis]. Rev Rhum Mal Osteoartic 1968, 35:50–52.

    PubMed  CAS  Google Scholar 

  22. Colao A, Di Somma C, Pivonello R, et al.: Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism. J Clin Endocrinol Metab 1999, 84:1919–1924.

    Article  PubMed  CAS  Google Scholar 

  23. Kaufman JM, Taelman P, Vermeulen A, Vanderweghe M: Bone mineral status in growth hormone deficient males with isolated and multiple pituitary deficiencies of childhood onset. J Clin Endocrinol Metab 1992, 74:118–123.

    Article  PubMed  CAS  Google Scholar 

  24. Baum HBA, Biller BMK, Finkelstein JS, et al.: Effects of physiologic growth hormone therapy on bone mineral density and body composition in patients with adult-onset growth hormone deficiency. Ann Int Med 1996, 125:883–890. Growth hormone administered to men with adult onset growth hormone deficiency at a dose adjusted according to serum IGF-1 levels increases bone density.

    PubMed  CAS  Google Scholar 

  25. O’Halloran DJ, Tsatsoulis A, Whitehouse RW, et al.: Increased bone density after recombinant human growth hormone (GH) therapy in adults with isolated GH defiency. J Clin Endocrinol Metab 1993, 76:1344–1348.

    Article  PubMed  Google Scholar 

  26. Kotzmann H, Riedl M, Bernecker P, et al.: Effect of long-term growth-hormone substitution therapy on bone mineral density and parameters of bone metabolism in adult patients with growth hormone deficiency. Calcif Tissue Int 1998, 62:40–46.

    Article  PubMed  CAS  Google Scholar 

  27. McGauley GA: Quality of life assessment before and after growth hormone treatment in adults with growth hormone deficiency. Acta Paediatr Scand 1989, 356:S70–72.

    Article  Google Scholar 

  28. Saeger W, Ludecke DK: Pituitary adenomas with hyperfunction of TSH. Frequency, histological classification, immunocytochemistry and ultrastructure. Virchows Arch [Pathol Anat] 1982, 394:255–267.

    Article  CAS  Google Scholar 

  29. Wilson CB: A decade of pituitary microsurgery. The Herbert Olivecrona lecture. J Neurosurg 1984, 61:814–833.

    Article  PubMed  CAS  Google Scholar 

  30. Mindermann T, Wilson CB: Thyrotropin-producing pituitary adenomas. J Neurosurg 1993, 79:521–527.

    Article  PubMed  CAS  Google Scholar 

  31. Losa M, Giovanelli M, Persani L, et al.: Criteria of cure and follow-up of central hyperthyroidism due to thyrotropinsecreting pituitary adenomas. J Clin Endocrinol Metab 1996, 81:3084–3090.

    Article  PubMed  CAS  Google Scholar 

  32. Faglia G, Beck-Peccoz P, Piscitelli G, Medri G: Inappropriate secretion of thyrotropin by the pituitary. Horm Res 1987, 26:79–99.

    Article  PubMed  CAS  Google Scholar 

  33. Kiso Y, Yoshida K, Kaise K, et al.: A case of thyrotropin (TSH)-secreting tumor complicated by periodic paralysis. Jpn J Med 1990, 29:399–404.

    PubMed  CAS  Google Scholar 

  34. Eriksen EF, Mosekilde L, Melsen F: Trabecular bone remodeling and bone balance in hyperthyroidism. Bone 1985, 6:421–428.

    Article  PubMed  CAS  Google Scholar 

  35. Cummings SR, Nevitt MC, Browner WS, et al.: Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995, 332:767–773.

    Article  PubMed  CAS  Google Scholar 

  36. Mosekilde L: Consequences of the remodelling process for vertebral trabecular bone structure: a scanning electron microscopy study (uncoupling of unloaded structures). Bone Miner 1990, 10:13–35.

    Article  PubMed  CAS  Google Scholar 

  37. Toh SH, Claunch BC, Brown PH: Effect of hyperthyroidism and its treatment on bone mineral content. Arch Intern Med 1985, 145:883–886.

    Article  PubMed  CAS  Google Scholar 

  38. Wejda B, Hintze G, Katschinski B, Olbricht T, Benker G: Hip fractures and the thyroid: a case-control study. J Intern Med 1995, 237:241–247.

    Article  PubMed  CAS  Google Scholar 

  39. Engel AG: Neuromuscular manifestations of Graves’ disease. Mayo Clin Proc 1972, 47:919–925.

    PubMed  CAS  Google Scholar 

  40. Diamond T, Vine J, Smart R, Butler P: Thyrotoxic bone disease in women: a potentially reversible disorder. Ann Intern Med 1994, 120:8–11.

    PubMed  CAS  Google Scholar 

  41. Ross EJ, Marshall-Jones P, Friedman M: Cushing’s syndrome: diagnostic criteria. Q J Med 1966, 35:149–192.

    PubMed  CAS  Google Scholar 

  42. Soffer LJ, Iannaccone A, Gabrilove JL: Cushing’s syndrome: a study of fifty patients. Am J Med 1961, 30:129–146.

    Article  Google Scholar 

  43. Sharon P, Kaplinsky N, Leiba S, Frankl O: Aseptic necrosis of head of femur: presenting manifestation in Cushing’s disease. J Rheumatol 1977, 4:73–75.

    PubMed  CAS  Google Scholar 

  44. Arima K, Higuchi M, Yoshizawa S, et al.: Improvement of systemic lupus erythematosus activity by the association of delayed onset Cushing’s syndrome. J Rheumatol 1998, 25:2456–2458.

    PubMed  CAS  Google Scholar 

  45. Noguchi Y, Tamai H, Fujisawa K, et al.: Systemic lupus erythematosus after pituitary adenomectomy in a patient with Cushing’s disease [letter]. Curr Opin Rheumatol 1998, 48:670–672.

    CAS  Google Scholar 

  46. Benhamou CL, Halimi D, Luton JP, et al.: [Osteoarticular manifestations in adrenal insufficiency]. Rev Rhum Mal Osteoartic 1984, 51:69–74.

    PubMed  CAS  Google Scholar 

  47. Da Silva JA, Larbre JP, Seed MP, et al.: Sex differences in inflammation induced cartilage damage in rodents. The influence of sex steroids. J Rheumatol 1994, 21:330–337.

    PubMed  Google Scholar 

  48. Cutolo M, Balleari E, Giusti M, Intra E, Accardo S: Androgen replacement therapy in male patients with rheumatoid arthritis. Arthritis Rheum 1991, 34:1–5.

    Article  PubMed  CAS  Google Scholar 

  49. Hall GM, Daniels M, Huskisson EC, Spector TD: A randomised controlled trial of the effect of hormone replacement therapy on disease activity in postmenopausal rheumatoid arthritis. Ann Rheum Dis 1994, 53:112–116.

    Article  PubMed  CAS  Google Scholar 

  50. Jungers P, Dougados M, Pelissier C, et al.: Influence of oral contraceptive therapy on the activity of systemic lupus erythematosus. Arthritis Rheum 1982, 25:618–623.

    Article  PubMed  CAS  Google Scholar 

  51. Julkunen HA: Oral contraceptives in systemic lupus erythematosus: side-effects and influence on the activity of SLE. Scand J Rheumatol 1991, 20:427–433.

    Article  PubMed  CAS  Google Scholar 

  52. Lahita RG, Bradlow L, Fishman J, Kunkel HG: Estrogen metabolism in systemic lupus erythematosus: patients and family members. Arthritis Rheum 1982, 25:843–846.

    Article  PubMed  CAS  Google Scholar 

  53. Hazes JM, Silman AJ, Brand R, et al.: Influence of oral contraception on the occurrence of rheumatoid arthritis in female sibs. Scand J Rheumatol 1990, 19:306–310.

    Article  PubMed  CAS  Google Scholar 

  54. Hazes JM, van Zeben D: Oral contraception and its possible protection against rheumatoid arthritis. Ann Rheum Dis 1991, 50:72–74.

    Article  PubMed  CAS  Google Scholar 

  55. Spector TD, Hochberg MC: The protective effect of the oral contraceptive pill on rheumatoid arthritis: an overview of the analytic epidemiological studies using meta-analysis. J Clin Epidemiol 1990, 43:1221–1230.

    Article  PubMed  CAS  Google Scholar 

  56. Antunes JL, Housepian EM, Frantz AG, et al.: Prolactinsecreting pituitary tumors. Ann Neurol 1977, 2:148–153.

    Article  Google Scholar 

  57. Burrow GN, Wortzman G, Rewcastle NB, Holgate RC, Kovacs K:Microadenomas of the pituitary and abnormal sellar tomograms in an unselected autopsy series. N Engl J Med 1981, 304:156–158.

    Article  PubMed  CAS  Google Scholar 

  58. Kleinberg DL, Noel GL, Frantz AG: Galactorrhea: a study of 235 cases including 48 with pituitary tumors. N Engl J Med 1977, 296:589–600.

    Article  PubMed  CAS  Google Scholar 

  59. Klibanski A, Neer RM, Beitins IZ, et al.: Decreased bone density in hyperprolactinemic women. N Engl J Med 1980, 303:1511–1514.

    Article  PubMed  CAS  Google Scholar 

  60. Finkelstein JS, Klibanski A, Neer RM, et al.: Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 1989, 69:776–783.

    Article  PubMed  CAS  Google Scholar 

  61. Klibanski A, Greenspan SL: Increase in bone mass after treatment of hyperprolactinemic amenorrhea. N Engl J Med 1986, 315:542–546.

    Article  PubMed  CAS  Google Scholar 

  62. Klibanski A, Biller BMK, Rosenthal DI, Saxe V: Effects of prolactin and estrogen deficiency in amenorrheic bone loss. J Clin Endocrinol Metab 1988, 67:124–130.

    Article  PubMed  CAS  Google Scholar 

  63. Smith PE: The effect of hypophysectomy upon the involution of the thymus in the rat. Anat Rec 1930, 47:119–129.

    Article  Google Scholar 

  64. Nagy E, Berczi I: Immunodeficiency in hypophysectomized rats. Acta Endocrinol (Copenh) 1978, 89:530–537.

    CAS  Google Scholar 

  65. Bernton EW, Meltzer MS, Holaday JW: Suppression of macrophage activation and T-lymphocyte function in hypoprolactinemic mice. Science 1988, 239:401–404.

    Article  PubMed  CAS  Google Scholar 

  66. Sanchez RM, Umbert MP: Psoriasis in association with prolactinoma: three cases. Br J Dermatol 2000, 143:864–867.

    Article  Google Scholar 

  67. Weber G, Frey H: [Treatment of psoriasis arthropathica with bromocriptine]. Z Hautkr 1986, 61:1456–1466.

    PubMed  CAS  Google Scholar 

  68. Hedner LP, Bynke G: Endogenous iridocyclitis relieved during treatment with bromocriptine. Am J Ophthalmol 1985, 100:618–619.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. NYU School of Medicine, 423 East 23rd Street, 10010, New York, NY, USA

    Stavros Stavrou MD & David L. Kleinberg MD

Authors
  1. Stavros Stavrou MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David L. Kleinberg MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stavrou, S., Kleinberg, D.L. Rheumatic manifestations of pituitary tumors. Curr Rheumatol Rep 3, 459–463 (2001). https://doi.org/10.1007/s11926-996-0018-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-996-0018-2

Keywords

Search

Navigation